Related Experiment Video

Updated: Jul 22, 2025

Author Spotlight: Advancing the Analysis of Plasma Extracellular Vesicle Proteome for Cardiovascular Biomarker Studies
05:30

Author Spotlight: Advancing the Analysis of Plasma Extracellular Vesicle Proteome for Cardiovascular Biomarker Studies

Published on: January 31, 2025

515

The secretome as a biomarker and functional agent in heart failure

Obed O Nyarko1,2, Carmen C Sucharov2

  • 1Integrative Physiology Graduate Program, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.

The Journal of Cardiovascular Aging
|July 24, 2023
PubMed

Insights

The secretome, a collection of secreted factors, plays a crucial role in heart failure (HF) development and progression. Understanding these molecules offers new avenues for HF diagnosis and therapy.

Area of Science:

  • Cardiovascular Biology
  • Molecular Medicine
  • Biochemistry

Background:

  • Heart failure (HF) is a complex disease with intricate molecular underpinnings.
  • Recent research highlights the significance of the secretome in HF pathogenesis.
  • The secretome comprises various secreted factors influencing cellular processes.

Purpose of the Study:

  • To provide a comprehensive review of the secretome's role in heart failure.
  • To explore the diagnostic and therapeutic potential of secretome research in HF.
  • To discuss challenges and future directions in secretome investigation.

Main Methods:

  • Literature review of scientific advancements in secretome research related to HF.
  • Analysis of secreted factors such as proteins, growth factors, cytokines, and microRNAs.
  • Examination of the impact of secretome on cellular signaling, angiogenesis, fibrosis, and inflammation.

Main Results:

  • Secreted factors influence key pathological processes in HF, including cardiac remodeling and inflammation.
  • The secretome has roles in both cardioprotection and cardiotoxicity.
  • Secretome analysis reveals potential for novel biomarker discovery in HF.

Conclusions:

  • The secretome is integral to HF onset, progression, and response to treatment.
  • Secretome research offers significant potential for improved HF diagnosis, risk stratification, and monitoring.
  • Targeting the secretome presents promising avenues for novel therapeutic strategies in heart failure.

Keywords:
Secretomebiomarkercirculating microRNAcirculating proteinheart failure

More Related Videos

A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay10:12

A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay

Published on: August 8, 2013

16.8K
Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

5.3K

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
16
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
119
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
201
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Overview of Exosomes01:36

Overview of Exosomes

Exosomes are stable, lipid bilayer-enclosed vesicles capable of crossing biological barriers. They can carry a wide range of molecules required for intercellular communication. Once exosomes are released from the cell where they originated, they enter a recipient cell through various pathways such as fusion, receptor-mediated endocytosis, macropinocytosis, and phagocytosis.
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
2.8K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
465